Abstract
The objective of this study was to evaluate the clinical benefit and the side effects of high dosages of betahistine dihydrochloride (288–480 mg/day) in patients with severe Menière’s disease (MD). In this case series 11 patients with MD who had not responded sufficiently to a dosage of 144 mg/day of betahistine dihydrochloride were treated on an individual basis with daily dosages between 288 and 480 mg of betahistine dihydrochloride. The number of attacks per month and the side effects were monitored. Non-parametric tests were used for statistical analysis. As a result, the frequency and the severity of vertigo were significantly reduced in all patients. The side effects were mild, self-limiting, and did not require any change in the treatment strategy. Despite the considerable limitations of an observational study—in particular in MD—high dosages of betahistine dihydrochloride between 288 and 480 mg/day seem to be effective in patients who do not sufficiently respond to lower dosages. Moreover, such dosages are well tolerated.
References
Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Meniere’s disease. American Academy of Otolaryngology-Head and Neck Foundation, Inc. Otolaryngol Head Neck Surg. (1995) 113(3):181–185
Merchant SN, Adams JC, Nadol JB Jr (2005) Pathophysiology of Meniere’s syndrome: are symptoms caused by endolymphatic hydrops? Otol Neurotol 26(1):74–81
Dieterich M, Brandt T (1999) Episodic vertigo related to migraine (90 cases): vestibular migraine? J Neurol 246(10):883–892
Guilemany JM, Martinez P, Prades E, Sanudo I, De Espana R, Cuchi A (2004) Clinical and epidemiological study of vertigo at an outpatient clinic. Acta Otolaryngol 124(1):49–52
Neuhauser H, Leopold M, von Brevern M, Arnold G, Lempert T (2001) The interrelations of migraine, vertigo, and migrainous vertigo. Neurology 56(4):436–441
van Cruijsen N, Jaspers JP, van de Wiel HB, Wit HP, Albers FW (2006) Psychological assessment of patients with Meniere’s disease. Int J Audiol 45(9):496–502
Eckhardt-Henn A, Best C, Bense S, Breuer P, Diener G, Tschan R et al (2008) Psychiatric comorbidity in different organic vertigo syndromes. J Neurol 255(3):420–428
Sajjadi H, Paparella MM (2008) Meniere’s disease. Lancet 372(9636):406–414
Strupp M, Hupert D, Frenzel C, Wagner J, Hahn A, Jahn K et al (2008) Long-term prophylactic treatment of attacks of vertigo in Meniere’s disease—comparison of a high with a low dosage of betahistine in an open trial. Acta Otolaryngol 128(5):520–524
Jeck-Thole S, Wagner W (2006) Betahistine: a retrospective synopsis of safety data. Drug Saf 29(11):1049–1059
James AL, Burton MJ (2001) Betahistine for Meniere’s disease or syndrome. Cochrane Database Syst Rev (1): CD001873
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lezius, F., Adrion, C., Mansmann, U. et al. High-dosage betahistine dihydrochloride between 288 and 480 mg/day in patients with severe Menière’s disease: a case series. Eur Arch Otorhinolaryngol 268, 1237–1240 (2011). https://doi.org/10.1007/s00405-011-1647-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00405-011-1647-2